CareRx 과거 순이익 실적
과거 기준 점검 3/6
CareRx은 연평균 63.1%의 비율로 수입이 증가해 온 반면, Consumer Retailing 산업은 수입이 0.9% 감소했습니다. 매출은 연평균 6.6%의 비율로 증가했습니다. CareRx의 자기자본이익률은 24.5%이고 순이익률은 7.1%입니다.
핵심 정보
63.13%
순이익 성장률
67.43%
주당순이익(EPS) 성장률
| Consumer Retailing 산업 성장률 | 10.26% |
| 매출 성장률 | 6.65% |
| 자기자본이익률 | 24.52% |
| 순이익률 | 7.13% |
| 최근 순이익 업데이트 | 30 Jun 2026 |
최근 과거 실적 업데이트
Recent updates
분석 기사 • Aug 01
Earnings Miss: CareRx Corporation Missed EPS By 60% And Analysts Are Revising Their Forecasts
It's been a good week for CareRx Corporation ( TSE:CRRX ) shareholders, because the company has just released its...
내러티브 업데이트 • Jun 16
CRRX: Slightly Lower Growth Assumptions Will Still Support Long Term Upside
Analysts have adjusted their CareRx price target from CA$4.50 to CA$4.25, citing updated assumptions related to slightly lower revenue growth, a modestly adjusted discount rate, a marginally different profit margin outlook, and a small change in the expected future P/E. What's in the News No recent CareRx news items or key developments were provided in the available sources.
내러티브 업데이트 • Jun 01
CRRX: Share Repurchases And Higher Future P/E Will Support Upside Potential
Narrative Update on CareRx The average analyst price target for CareRx has shifted from CA$5.38 to CA$5.14. Analysts point to updated fair value estimates, a slightly higher discount rate, more cautious revenue growth assumptions, lower projected profit margins, and a higher future P/E multiple as key drivers of the change.내러티브 업데이트 • May 04
CRRX: Completed Buyback And Stable Assumptions Will Support Long Term Upside
Analysts have nudged their CareRx price target slightly higher to CA$4.50, reflecting modest adjustments to the discount rate, revenue growth assumptions, profit margin outlook and future P/E expectations. What's in the News CareRx completed a share repurchase of 246,069 shares between October 1, 2025 and March 4, 2026, equal to 0.39% of its shares, for a total of CA$0.49 million (Key Developments).내러티브 업데이트 • Apr 19
CRRX: Share Repurchase And Steady Assumptions Will Support Long Term Upside
Analysts have made slight adjustments to their CareRx price targets, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. Their fair value estimate remains steady at CA$4.50.내러티브 업데이트 • Apr 05
CRRX: Share Repurchase And Margin Outlook Will Support Long Term Upside
Analysts have modestly revised their CareRx price target to CA$4.50, reflecting updated assumptions for discount rate, revenue growth, profit margins and future P/E, which keep the fair value estimate steady at CA$4.50. What's in the News CareRx completed a share repurchase of 246,069 shares, representing 0.39% of its shares, for a total of CA$0.49 million under the buyback announced on September 15, 2025 (Key Developments).내러티브 업데이트 • Mar 22
CRRX: Share Repurchases And Higher Assumed P/E Will Support Future Upside
Analysts have adjusted their CA$ fair value estimate for CareRx from about CA$5.08 to roughly CA$5.38, reflecting updated views on revenue growth, profit margins, and future P/E assumptions. What's in the News CareRx completed a share repurchase program, buying back 246,069 shares between October 1, 2025 and March 4, 2026, equal to 0.39% of its shares, for a total of CA$0.49 million (Key Developments).내러티브 업데이트 • Mar 07
CRRX: Improved Profit Outlook And Lower P/E Will Support Future Upside
Analysts have adjusted their CareRx price target slightly higher to CA$5.08 from CA$4.92, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Valuation Changes Fair Value: CA$5.08, up slightly from CA$4.92.내러티브 업데이트 • Feb 21
CRRX: Lower Future P/E Will Support Stronger Shareholder Returns
Analysts have trimmed their target price on CareRx to CA$4.92. They link this move to slightly higher discount rate assumptions and a modestly lower revenue growth outlook, partially balanced by a small improvement in expected profit margins and a lower future P/E estimate.내러티브 업데이트 • Feb 06
CRRX: Refined Earnings Assumptions Will Support Stronger Long Term Upside Potential
Analysts have slightly adjusted their price target on CareRx, citing updated assumptions around revenue growth, profit margins, discount rate and future P/E that fine tune rather than overhaul their previous fair value view. Valuation Changes Fair Value: Unchanged at 4.5x, indicating no shift in the overall valuation anchor used in the model.내러티브 업데이트 • Jan 23
CRRX: Future Earnings Power Will Support Refined Fair Value Upside
Analysts have slightly adjusted their price target on CareRx, reflecting modest tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. Together these changes point to a more refined view of the company’s fair value around $4.50.내러티브 업데이트 • Jan 09
CRRX: Future Earnings Power Will Drive Repriced Market Expectation
The analyst price target for CareRx has shifted from US$2.25 to US$4.50, with analysts attributing this change to updated assumptions about revenue growth, profitability, and future P/E. What's in the News Between September 15, 2025 and September 30, 2025, CareRx reported no share repurchases under its existing buyback program, with 0 shares repurchased for CAD 0 million in that period (Key Developments).내러티브 업데이트 • Dec 24
CRRX: Higher Future Earnings Multiple Will Drive Stronger Shareholder Returns
Analysts have nudged their price target for CareRx slightly higher, raising it by about $0.06 per share. This reflects modestly stronger expectations for revenue growth and valuation multiples, despite a more cautious view on profit margins.내러티브 업데이트 • Dec 10
CRRX: Upcoming Share Buybacks Will Support Stronger Future Shareholder Returns
Narrative Update on CareRx Analysts have modestly increased their price target on CareRx to reflect a slightly higher valuation multiple and stable expectations for revenue growth and profit margins. This translates into a small upward adjustment in projected equity value by a few cents per share.내러티브 업데이트 • Nov 26
CRRX: Share Repurchase Program Will Drive Stronger Performance Ahead
Analysts have raised their price target for CareRx, increasing the fair value estimate from $4.00 to $4.86. This change reflects improved revenue growth expectations and a more favorable profit margin outlook.분석 기사 • Sep 11
Is CareRx (TSE:CRRX) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
새로운 내러티브 • Apr 07
North Burnaby Fulfillment Center And European Automation Will Improve Operations
Debt restructuring and cost-saving measures likely increase net margins and improve earnings by reducing interest expenses and operational costs.분석 기사 • Feb 11
Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues
It's not a stretch to say that CareRx Corporation's ( TSE:CRRX ) price-to-sales (or "P/S") ratio of 0.4x right now...분석 기사 • Oct 03
CareRx (TSE:CRRX) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Aug 11
Analyst Estimates: Here's What Brokers Think Of CareRx Corporation (TSE:CRRX) After Its Second-Quarter Report
Last week, you might have seen that CareRx Corporation ( TSE:CRRX ) released its quarterly result to the market. The...분석 기사 • Apr 22
Does CareRx (TSE:CRRX) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...분석 기사 • Mar 17
Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues Pushing Shares 28% Higher
CareRx Corporation ( TSE:CRRX ) shares have continued their recent momentum with a 28% gain in the last month alone...분석 기사 • Oct 19
CareRx (TSE:CRRX) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...분석 기사 • Aug 22
What You Can Learn From CareRx Corporation's (TSE:CRRX) P/S
It's not a stretch to say that CareRx Corporation's ( TSE:CRRX ) price-to-sales (or "P/S") ratio of 0.3x right now...분석 기사 • Sep 22
CareRx (TSE:CRRX) Has A Somewhat Strained Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...매출 및 비용 세부 내역
매출 및 비용 세부 내역
CareRx가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 30 Jun 26 | 377 | 27 | 101 | 0 |
| 31 Mar 26 | 375 | 27 | 100 | 0 |
| 31 Dec 25 | 370 | 26 | 100 | 0 |
| 30 Sep 25 | 366 | 0 | 100 | 0 |
| 30 Jun 25 | 366 | -2 | 100 | 0 |
| 31 Mar 25 | 367 | -4 | 101 | 0 |
| 31 Dec 24 | 367 | -5 | 101 | 0 |
| 30 Sep 24 | 366 | -6 | 98 | 0 |
| 30 Jun 24 | 367 | -7 | 99 | 0 |
| 31 Mar 24 | 369 | -4 | 98 | 0 |
| 31 Dec 23 | 371 | -5 | 98 | 0 |
| 30 Sep 23 | 374 | -6 | 100 | 0 |
| 30 Jun 23 | 378 | -7 | 100 | 0 |
| 31 Mar 23 | 380 | -34 | 101 | 0 |
| 31 Dec 22 | 382 | -34 | 103 | 0 |
| 30 Sep 22 | 384 | -34 | 101 | 0 |
| 30 Jun 22 | 358 | -36 | 94 | 0 |
| 31 Mar 22 | 311 | -20 | 83 | 0 |
| 31 Dec 21 | 263 | -23 | 71 | 0 |
| 30 Sep 21 | 212 | -21 | 61 | 0 |
| 30 Jun 21 | 187 | -24 | 55 | 0 |
| 31 Mar 21 | 177 | -29 | 52 | 0 |
| 31 Dec 20 | 162 | -18 | 48 | 0 |
| 30 Sep 20 | 148 | -50 | 44 | 0 |
| 30 Jun 20 | 134 | -47 | 42 | 0 |
| 31 Mar 20 | 126 | -34 | 41 | 0 |
| 31 Dec 19 | 125 | -46 | 41 | 0 |
| 30 Sep 19 | 122 | -19 | 42 | 0 |
| 30 Jun 19 | 119 | -20 | 41 | 0 |
| 31 Mar 19 | 117 | -39 | 41 | 0 |
| 31 Dec 18 | 119 | -35 | 41 | 0 |
| 30 Sep 18 | 85 | -27 | 27 | 0 |
| 30 Jun 18 | 97 | -23 | 31 | 0 |
| 31 Mar 18 | 110 | -3 | 34 | 0 |
| 31 Dec 17 | 122 | -4 | 38 | 0 |
| 30 Sep 17 | 168 | -6 | 55 | 0 |
| 30 Jun 17 | 170 | -3 | 56 | 0 |
| 31 Mar 17 | 170 | -13 | 58 | 0 |
| 31 Dec 16 | 167 | -18 | 59 | 0 |
| 30 Sep 16 | 166 | -21 | 64 | 0 |
| 30 Jun 16 | 166 | -34 | 66 | 0 |
| 31 Mar 16 | 164 | -30 | 67 | 0 |
| 31 Dec 15 | 161 | -35 | 67 | 0 |
| 30 Sep 15 | 27 | -47 | 13 | 0 |
양질의 수익: CRRX는 CA$1.3M 규모의 큰 일회성 손실이 있어 30th June, 2026까지 지난 12개월 재무 결과에 영향을 미쳤습니다.
이익 마진 증가: CRRX는 과거에 흑자전환했습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: CRRX는 지난 5년 동안 흑자전환하며 연평균 63.1%의 수익 성장을 기록했습니다.
성장 가속화: CRRX는 지난해 흑자전환하여 5년 평균과 수익 성장률을 비교하기 어렵습니다.
수익 대 산업: CRRX는 지난해 흑자전환하여 지난 해 수익 성장률을 Consumer Retailing 업계(15.5%)와 비교하기 어렵습니다.
자기자본이익률
높은 ROE: CRRX의 자본 수익률(24.5%)은 높음으로 평가됩니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/06 23:32 |
| 종가 | 2026/08/06 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
CareRx Corporation는 11명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Kyle McPhee | ATB Cormark |
| Kyle McPhee | ATB Cormark Historical (Cormark Securities) |
| Doug Cooper | Beacon Securities Limited |